Clinical trial NCT06284161: QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up
Official title: Contribution of the Combined Quadriceps Test (QCT) in the Diagnosis, Mechanistic Understanding and Follow-up of Amyotrophic Lateral Sclerosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Amyotrophic Lateral Sclerosis
Keywords: Quadriceps Combined Test
Amyotrophic Lateral Sclerosis
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2024-02-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Multidisciplinary management of amyotrophic lateral sclerosis (ALS) can significantly increase survival but also improve the quality of life of patients. The evaluation of cortical-spinal motor neuron damage is currently based only on the assessment of clinical data. However, the alteration of the central motor pathway and conduction can be identified and quantified by different techniques using motor-evoked potentials (MEP). The combined quadriceps test (QCT) has been developed to assess central and peripheral motor pathway conduction. This test allows to quantify central and peripheral part of a mixed disorder, and to detect physiological hyporeflexia or hyperreflexia which, in the case of suspected ALS, can lead to interpretation problems.

The evolution of the QCT parameters during the course of pathology will lead to determine the preponderance of an initial central involvement, but also its extension throughout the pathology. The study of these parameters as well as the clinical course of the disease could reveal a correlation between peripheral and central involvement. This link would provide arguments in favor of pathophysiological hypotheses of disease onset and progression. From a prognostic point of view and depending on the quantification of central and peripheral involvement, the QCT would make it possible to characterize the different ALS phenotypes. This phenotypic characterization would help identify prognostic factors at diagnosis.

The investigators propose a cohort study with the exploration of central motor neuron damage by QCT during the course of ALS in order to provide arguments for a better mechanistic understanding and follow-up of this disease with a poor prognosis.


Eligibility criteria: Inclusion Criteria:

* A male or female patient of legal age with suspected ALS (bulbar or spinal) who meets the criteria for "possible", "probable" or "definite" ALS according to the Awaji criteria
* Able to give informed consent to participate in the research
* Enrolled in a Social Security plan

Exclusion Criteria:

* Pregnant or breastfeeding woman
* Severe progressive pathology other than ALS.
* Comorbidities with another neurological disease altering motor skills.
* Contraindication to trans-cranial magnetic stimulation: epilepsy, pacemaker, intracranial ferromagnetic foreign body (clip, aneurysm, implants)...
* Chronic alcoholism
* Cognitive disorders or major incapacity making it impossible to understand the study and sign an informed consent (fronto-temporal dementia, psychiatric conditions of psychotic type, language disorders)
* Refusal to participate.
* Patients under legal protection (guardianship, curators, safeguard of justice)

Primary outcomes:
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: At inclusion
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: Month 6
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: Month 12
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 18
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 24
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: At inclusion
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 6
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 12
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 18
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 24
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: At inclusion
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 6
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 12
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 18
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 24
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: At inclusion
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 6
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 12
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 18
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 24
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: At inclusion
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 6
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 12
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 18
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 24
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: At inclusion
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 6
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 12
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 18
measure: Parameters from the QCT (Quadriceps Combined Test)
timeFrame: month 24
Secondary outcomes:
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: At inclusion
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
measure: Clinical and paraclinical likely course data
timeFrame: Every 3 months up to 2 years
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU de Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Nathalie Guy
role: PRINCIPAL_INVESTIGATOR
References: